OmniAb and PepGen Reveal 2025 Financials and 2026 Clinical Roadmaps

The simultaneous release of full-year 2025 financial results from OmniAb and PepGen provides a compelling snapshot of the two primary engines driving modern biotechnology: the 'picks and shovels' platform model and the high-stakes therapeutic development model. As the industry moves into 2026, these reports underscore a shift toward fiscal discipline and a focus on high-value clinical milestones. For OmniAb, the year was defined by the continued expansion of its antibody discovery ecosystem, while PepGen solidified its position in the competitive neuromuscular disease space with its proprietary EDO platform.

OmniAb’s performance in 2025 highlights the resilience of the royalty-bearing platform model. By providing pharmaceutical partners with access to a suite of transgenic animals—including OmniRat, OmniChicken, and OmniMouse—the company has insulated itself from the binary risk of a single drug candidate. Throughout the fiscal year, OmniAb reported a steady increase in active programs, a critical metric for long-term revenue potential. The company’s strategy revolves around 'embedded value,' where the success of its 300+ partner programs translates into future milestone payments and royalties. This model is increasingly attractive to investors seeking exposure to biotech innovation without the volatility associated with individual clinical trial failures.

“

For OmniAb, the year was defined by the continued expansion of its antibody discovery ecosystem, while PepGen solidified its position in the competitive neuromuscular disease space with its proprietary EDO platform.

In contrast, PepGen’s 2025 results reflect the intensive capital requirements and focused execution of a clinical-stage therapeutic developer. The company is leveraging its Enhanced Delivery Oligonucleotide (EDO) technology to overcome the historical challenges of delivering genetic medicines to muscle tissue. The 2025 highlights centered on the progress of PGN-EDO51 for Duchenne Muscular Dystrophy (DMD) and PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1). For PepGen, the primary narrative is one of clinical validation. The market is closely watching for data that proves their EDO platform can achieve superior tissue penetration and exon-skipping levels compared to first-generation antisense oligonucleotides.

Financially, both companies entered 2026 with significant cash runways, a vital asset in a macroeconomic environment that remains cautious about pre-revenue biotech. OmniAb’s ability to generate near-term revenue through licensing fees and milestones provides a buffer that many of its peers lack. Meanwhile, PepGen’s successful capital raises in 2025 have extended its runway through key clinical readouts, reducing the immediate pressure for dilutive financing. This financial stability is a prerequisite for navigating the complex regulatory pathways and manufacturing hurdles inherent in advanced biologics and genetic therapies.